Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

被引：2

作者：

Melody, Megan ^{[1
]}

Epperla, Narendranath ^{[2
,3
]}

Shouse, Geoffrey ^{[4
]}

Romancik, Jason ^{[5
]}

Allen, Pamela ^{[5
]}

Moyo, Tamara K. ^{[6
]}

Kenkre, Vaishalee ^{[7
]}

Ollila, Thomas ^{[8
]}

Fitzgerald, Lindsey ^{[9
]}

Hess, Brian ^{[10
]}

David, Kevin ^{[11
]}

Herr, Megan M. ^{[12
]}

Odetola, Oluwatobi ^{[1
]}

Lin, Adam ^{[13
]}

Moreira, Jonathan ^{[13
]}

Ma, Shuo ^{[12
]}

Winter, Jane N. ^{[13
]}

Roy, Ishan ^{[14
]}

Stephens, Deborah ^{[15
]}

Danilov, Alexey

Shah, Nirav N. ^{[16
]}

Barta, Stefan K. ^{[17
]}

Cortese, Matthew ^{[12
]}

Cohen, Jonathon B. ^{[5
]}

Gordon, Leo I. ^{[13
]}

Karmali, Reem ^{[1
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, 676 N Saint Clair St,Suite 850, Chicago, IL 60611 USA

[2] Ohio State Univ, Arthur G James Canc Hosp, Columbus, OH USA

[3] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH USA

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[7] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[8] Brown Univ, Lifespan Canc Inst, Providence, RI USA

[9] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[10] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA

[11] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[12] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[13] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[14] Shirley Ryan Abil Lab, Chicago, IL USA

[15] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[16] Med Coll Wisconsin, MCW Canc Ctr, Milwaukee, WI USA

[17] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

来源：

BLOOD ADVANCES | 2024年 / 8卷 / 10期

关键词：

COMPOSITE LYMPHOMA; MULTICENTER; CANCER;

D O I：

10.1182/bloodadvances.2024012573

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2327 / 2331

页数：5

共 50 条

[21] Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy
Yang, Yang
Gu, Xiaolin
He, Jingsong
Hu, Yongxian
Cai, Zhen
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2024, 25 (08): : 719 - 722
[22] Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, Andreas
Mueller, Fabian
Mougiakakos, Dimitrios
Boeltz, Sebastian
Wilhelm, Artur
Aigner, Michael
Voelkl, Simon
Simon, David
Kleyer, Arnd
Munoz, Luis
Kretschmann, Sascha
Kharboutli, Soraya
Gary, Regina
Reimann, Hannah
Roesler, Wolf
Uderhardt, Stefan
Bang, Holger
Herrmann, Martin
Ekici, Arif Buelent
Buettner, Christian
Habenicht, Katharina Maria
Winkler, Thomas H.
Kroenke, Gerhard
Schett, Georg
NATURE MEDICINE, 2022, 28 (10) : 2124 - 2132
[23] Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia
Fraietta, Joseph A.
Lacey, Simon F.
Wilcox, Nicholas S.
Bedoya, Felipe
Chen, Fang
Orlando, Elena
Brogdon, Jennifer L.
Hwang, Wei-Ting
Frey, Noelle
Young, Regina M.
Pequignot, Edward
Ambrose, David E.
Levine, Bruce L.
Bitter, Hans
Porter, David L.
Xu, Jun
June, Carl H.
Melenhorst, Jan Joseph
BLOOD, 2016, 128 (22)
[24] Development of in vivo anti-CD19 CAR T-cell therapy based on chemically encapsulated lentiviral vectors
Mourlane, F.
Tesson, P.
Magliocco, C.
Duchene, C.
Girardon, M.
Lhuaire, M.
Leclere, L.
Maunichy, E.
Pacherie, R.
Vaillant, R.
Bauche, C.
HUMAN GENE THERAPY, 2021, 32 (19-20) : A37 - A37
[25] NEUROTOXICITY AS A POTENTIAL SURROGATE MARKER FOR THERAPEUTIC RESPONSE WITH COMMERCIAL ANTI-CD19 CAR T-CELL THERAPY
Yuen, Carlen
Riedell, Peter
Artz, Andrew
Kosuri, Satyajit
Kelly, Thomas
Wu, Shasha
Reder, Anthony
Rezania, Kourosh
Soliven, Betty
Xie, Tao
Mastrianni, James
Park, Deric
Klejch, Wesley
Ali, Saad
Bishop, Michael
NEURO-ONCOLOGY, 2020, 22 : 126 - 126
[26] Anti-CD19 CAR-T cell therapy for acquired hemophilia AIMMUNOTHERAPY
Christian R. Schultze-Florey
Felicitas R. Thol
Krasimira Aleksandrova
Kalin Stoyanov
Rodrigo Gutierrez Jauregui
Lubomir Arseniev
Jana Leise
Stephan Klöß
Florian H. Heidel
Andreas Tiede
Leukemia, 2025, 39 (4) : 980 - 982
[27] Development of In Vivo Anti-CD19 CAR T-Cell Therapy Based on Chemically Encapsulated Lentiviral Vectors
Mourlane, Frederic
Tesson, Pauline
Duchene, Charles
Girardon, Maxime
Lhuaire, Marion
Leclere, Laurence
Maunichy, Eva
Pacherie, Rachel
Tezgel, Ozgul
Vaillant, Renaud
Bauche, Cecile
MOLECULAR THERAPY, 2021, 29 (04) : 325 - 326
[28] Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed BCell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy
Yang, Fan
Liu, Rui
Xu, Teng
Zheng, Peihao
Feng, Shaomei
Guo, Yuelu
Ma, Lixia
Shi, Hui
Deng, Biping
Ke, Xiaoyan
Wu, Tong
Hu, Kai
BLOOD, 2022, 140 : 10384 - 10385
[29] Nivolumab as Salvage Therapy in Patients who Failed to Achieve Complete Remission after anti-CD19 CAR T-cell Therapy for DLBCL
Gazeau, Nicolas
Beauvais, David
Manier, Salomon
de la Contrie, Marie De Charette
Srour, Micha
Varlet, Pauline
Labalette, Myriam
Morschhauser, Franck
Yakoub-Agha, Ibrahim
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 231 - 232
[30] CD19+lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation
Martinez-Romera, Isabel
Galan-Gomez, Victor
Gonzalez-Martinez, Berta
Garcia, Pilar Guerra
Pacheco, Sonsoles San Roman
Sanchez, Dolores Corral
del Castillo, Yasmina Mozo
Sanchez, David Bueno
Sisinni, Luisa
Guerrero, Alba Gonzalez
Damaso, Serafin Castellano
Zapardiel, Elena Sanchez
Caracuel, Beatriz Ruz
Perez, Antonio Balas
Perez-Martinez, Antonio
FRONTIERS IN IMMUNOLOGY, 2022, 13

← 1 2 3 4 5 →